AI Article Synopsis
- A study was conducted to assess how fibroblast activation protein inhibitor (FAPI)-directed imaging compares to traditional imaging in staging and managing digestive system tumors.
- Out of 32 patients with various digestive tumors, FAPI imaging changed the staging for 46.9% of them, affecting how their treatment was approached, especially for those with hepatocellular carcinoma (HCC) and pancreatic duct adenocarcinoma (PDAC).
- The findings suggest that FAPI-guided imaging could significantly alter patient management and could lead to more frequent use of this imaging method in clinical settings for specific tumor types.
Article Abstract
Purpose: We aimed to determine the impact of fibroblast activation protein inhibitor (FAPI)-directed molecular imaging on staging and therapeutic management in patients affected with digestive system tumors when compared with guideline-compatible imaging (GCI).
Patients And Methods: Thirty-two patients with tumors of the digestive system were included: colon adenocarcinoma, 2/32 (6.3%); hepatocellular carcinoma (HCC), 6/32 (18.8%); pancreatic duct adenocarcinoma (PDAC), 6/32 (18.8%), and gastroenteropancreatic neuroendocrine neoplasms, 18/32 (56.3%). All patients underwent GCI and 68 Ga-FAPI-04 PET/CT within median 4 days. Staging outcomes and subsequent treatment decisions were compared between GCI and 68 Ga-FAPI-04 PET/CT.
Results: Compared with GCI, 68 Ga-FAPI-04 PET/CT led to staging changes in 15/32 patients (46.9%). Among those, downstaging was recorded in 3/15 cases (20.0%) and upstaging in the remaining 12/15 patients (HCC, 4/12 [33.3%]; PDAC, 4/12 [33.3%]; neuroendocrine neoplasms, 3/12 [25%]; colon adenocarcinoma, 1/12 [8.3%]). Therapeutic management was impacted in 8/32 patients (25.0%), including 4 instances of major and 4 instances of minor therapeutic changes. The highest proportion of treatment modifications was observed in patients diagnosed with PDAC and HCC in 6/8 (75%).
Conclusions: In patients affected with digestive system tumors, 68 Ga-FAPI-04 PET/CT resulted in staging changes in more than 46% and therapeutic modifications in 25% of the cases, in particular in patients with HCC and PDAC. In clinical routine, such findings may favor a more widespread adoption of FAP-directed imaging in those tumor types.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762711 | PMC |
| http://dx.doi.org/10.1097/RLU.0000000000004480 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contrasting Molecular Imaging Findings in Hepatocellular Carcinoma Using Dual Positron Emission Tomography Modalities.
Cureus
December 2024
Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, JOR.
Fibroblast activation protein (FAPI) has been recently incorporated as a molecular imaging radiotracer for the evaluation of epithelial neoplasms that support or complement the role of [F]Fluorodeoxyglucose ([F]FDG) in many cancer subtypes since its development. Both radiotracers have been shown to have diagnostic, prognostic, and predictive value for several neoplasms. Herein, we present a 73-year-old male patient with a complex medical and oncological history who was recently diagnosed with hepatocellular carcinoma (HCC).
View Article and Find Full Text PDFDevelopment of [Ga]Ga/[Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention.
J Med Chem
January 2025
Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Fibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts (CAFs), represents a promising target for cancer diagnosis and therapy. Hypoxia is a common feature of solid tumors. A bivalent agent, DOTA-NI-FAPI-04 (), was developed by incorporating hypoxia-sensitive nitroimidazole (NI) into the FAP-targeting agent FAPI-04.
View Article and Find Full Text PDFDistinguishing benign from malignant lesions with high [ Ga]Ga-FAPI-04 uptake in oncology patients: Insights from dynamic total-body [ Ga]Ga-FAPI-04 PET/CT.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, China.
Background And Purpose: While [ Ga]Ga-FAPI-04 PET/CT is widely used in various malignant tumors diagnosis, its specificity is challenged by high uptake in benign lesions such as inflammatory lymphadenopathy, bone fractures, and degenerative changes. This study aimed to quantitatively assess and characterize the metabolic heterogeneity of [ Ga]Ga-FAPI-04 uptake in benign and malignant lesions using dynamic total-body PET/CT.
Methods: Dynamic total-body [ Ga]Ga-FAPI-04 PET/CT scans (0-60 min post-injection) were performed on 17 oncology patients.
Primary Extraosseous Ewing Sarcoma on 18 F-FDG and 68 Ga-FAPI-04 PET/CT.
Clin Nucl Med
November 2024
Department of Pathology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Primary extraosseous Ewing sarcoma of the nasal cavity is rare. A 17-year-old man underwent 18 F-FDG and 68 Ga-FAPI-04 PET/CT for a nasal mass. The mass showed avid FDG uptake but weak FAPI uptake.
View Article and Find Full Text PDFHepatic epithelioid Hemangioendothelioma presenting synchronously with hepatocellular carcinoma-a case report.
Oxf Med Case Reports
November 2024
Department of Radiology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Backgrounds: Primary hepatic epithelioid hemangioendothelioma (HEHE) is a rare neoplasm of vascular origin with varying biologic behavior, making it challenging to diagnose.
Case Presentation: We present a case of synchronous hepatocellular carcinoma (HCC) and HEHE in a 43-year-old Chinese male patient. Multiple hypoechoic liver lesions were depicted, but no specific imaging findings were detected on enhanced computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!